OSE Immunotherapeutics SA Sustainability Profile
OSE Immunotherapeutics SA, headquartered in France, is a pioneering biotechnology company specialising in immunotherapy solutions for cancer and autoimmune diseases. Founded in 2012, OSE has rapidly established itself as a leader in the biopharmaceutical industry, focusing on the development of innovative therapeutic products that harness the body’s immune system. The company’s core offerings include a diverse pipeline of monoclonal antibodies and vaccine candidates, distinguished by their unique mechanisms of action. Notable achievements include strategic partnerships and collaborations that enhance its market position, particularly in Europe and North America. OSE Immunotherapeutics is committed to advancing the frontiers of immunotherapy, aiming to provide effective treatments that address unmet medical needs in oncology and beyond.
DitchCarbon Score
How does OSE Immunotherapeutics SA's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
OSE Immunotherapeutics SA's score of 29 is lower than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
OSE Immunotherapeutics SA's reported carbon emissions
OSE Immunotherapeutics SA, headquartered in France, currently does not have available carbon emissions data for the most recent year. As a result, specific figures regarding their total emissions, including Scope 1, 2, and 3, are not provided. The company has not outlined any reduction targets or commitments through initiatives such as the Science Based Targets initiative (SBTi) or other climate pledges. This absence of data suggests that OSE Immunotherapeutics SA may still be in the early stages of formalising its climate commitments or reporting practices. In the context of the biopharmaceutical industry, many companies are increasingly focusing on sustainability and carbon reduction strategies. However, without specific emissions data or targets, it is challenging to assess OSE Immunotherapeutics SA's position relative to industry standards.
How Carbon Intensive is OSE Immunotherapeutics SA's Industry?
How Carbon Intensive is OSE Immunotherapeutics SA's Location?
OSE Immunotherapeutics SA's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
OSE Immunotherapeutics SA has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Jiangsu Chia Tai-Tianqing Pharmaceutical Co. Ltd
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.